Theo Heller

Theo Heller

Auto-generated profile, based on publicly available information

Theo Heller

Liver Diseases Branch, NIDDK, NIH, Bethesda, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
NHNadeem Hussain
Nadeem Hussain
JFJordan J. Feld
Jordan J. Feld
DKDavid E. Kleiner
David E. Kleiner
JHJay H. Hoofnagle
Jay H. Hoofnagle
DGDr. Garcia-Eulate
Dr. Garcia-Eulate
THTheo Heller
Theo Heller
Chronic granulomatous disease (CGD) is a rare congenital disorder characterized by repeated bacterial and fungal infections. Aside from a high incidence of liver abscess, little is known about hepatic involvement in CGD. The aim of this study was to describe the spectrum of liver abnormalities seen in CGD. The charts of 194 patients with CGD followed at the NIH were reviewed, with a focus on liver abnormalities. Liver enzyme elevations occurred on at least one occasion in 73% of patients during a mean of 8.9 years of follow-up. ALT elevations were generally transient. Although transient alkaline phosphatase (ALP) elevations were also common, persistent ALP elevations lasting up to 17.6 years were seen in 25% of patients. Liver abscess occurred in 35% of patients. Drug-induced hepatotoxicity was documented in 15% of patients but likely occurred more frequently. Hepatomegaly was found in 34% and splenomegaly in 56% of patients. Liver histology showed granulomata in 75% and lobular hepatitis in 90% of specimens. Venopathy of the portal vein was common (80%) and associated with splenomegaly. Venopathy of the central vein was also common (63%) and was associated with the number of abscess episodes. Nodular regenerative hyperplasia (NRH) was seen in 9 patients, including 6 of 12 autopsy specimens. Conclusion: Liver enzyme abnormalities occur frequently in patients with CGD. In addition to liver abscesses and granulomata, drug hepatotoxicity is likely underappreciated. Vascular lesions such as venopathy and—to a lesser extent—NRH are common. The cause and clinical consequences of venopathy await prospective evaluation. (Hepatology 2007;45:675–683.)

1 June 2008 in Gastroenterology
Verified
Journal Article
Open access
PDF file
JFJordan J. Feld
Jordan J. Feld
NHNadeem Hussain
Nadeem Hussain
EWElizabeth C. Wright
Elizabeth C. Wright
DKDavid E. Kleiner
David E. Kleiner
JHJay H. Hoofnagle
Jay H. Hoofnagle
THTheo Heller
Theo Heller
Background & Aims: Chronic granulomatous disease (CGD) is a rare genetic disorder, predisposing affected individuals to recurrent infectious complications and shortened survival. Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension. Methods: To evaluate the impact of noncirrhotic portal hypertension on survival in CGD, all records from 194 patients followed up at the National Institutes of Health with CGD were reviewed. Cox proportional hazards regression was used to determine factors associated with mortality. Results: Twenty-four patients died, all from infectious complications. By Cox regression, factors associated with mortality were as follows: (1) decreases in platelet count (>9000/μL/y; hazard ratio, 4.7; P = .007), (2) alkaline phosphatase level increases (>0.25/y; hazard ratio, 4.5; P = .01) and (3) history of liver abscess (hazard ratio, 3.1; P = .03). By regression analysis, decreasing platelet count was associated with increasing portal vein diameter, splenomegaly, increased serum immunoglobulin G level, and increasing number of alanine aminotransferase increases; greater number of alkaline phosphatase level increases and abscess were both associated with increasing age and number of infections. Prospective evaluation revealed increased hepatic-venous pressure gradients in 2 patients with progressive thrombocytopenia, suggestive of portal hypertension. Conclusions: These data suggest mortality in patients with CGD is associated with the development of noncirrhotic portal hypertension, likely owing to injury to the microvasculature of the liver from repeated systemic and hepatic infections. The slope of decline in platelet count may be a useful measure of progression of portal hypertension over time. Furthermore, the data illustrate the potential independent effect of portal hypertension on clinical outcome outside the setting of cirrhosis.

29 December 2010 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RLR. Loomba
R. Loomba
MRM. M. Rivera
M. M. Rivera
RMR. McBurney
R. McBurney
YPY. Park
Y. Park
VHV. Haynes‐Williams
V. Haynes‐Williams
THT. Heller
T. Heller
Aliment Pharmacol Ther 2011; 33: 559–565Summary: Background  Acute hepatitis C has variable modes of presentation and frequently results in chronic infection. Its optimal management has yet to be defined.Aim  To establish natural history and complications of treatment of acute hepatitis C.Methods  Data from all patients presenting with acute hepatitis C to the National Institutes of Health between 1994 and 2007 were reviewed.Results  Twenty‐five patients were identified. Symptoms were reported by 80% and jaundice by 40%. Aminotransferase levels and hepatitis C virus (HCV) RNA levels fluctuated greatly; 18% of patients were intermittently negative for HCV RNA. Five patients recovered spontaneously whereas 20 developed chronicity or received interferon‐based therapy during the acute phase. Among 15 patients treated during the acute phase with peginterferon with or without ribavirin for 24 weeks, all became HCV RNA negative within 4–8 weeks, and all except two (HIV‐positive) achieved a sustained virological response. Side effects (particularly psychiatric) were common and limited treatment in 30%.Conclusions  Among 25 patients with acute HCV infection, fluctuating illness was common and spontaneous recovery occurred in only 20%. Anti‐viral treatment with a 24‐week course of peginterferon and ribavirin was highly effective, but marked by frequent and severe side effects.

13 August 2017 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
MAManish Arora
Manish Arora
PBPreet Bagi
Preet Bagi
ASAnna Strongin
Anna Strongin
JHJennifer Heimall
Jennifer Heimall
XZXiongce Zhao
Xiongce Zhao
THTheo Heller
Theo Heller

3 August 2015 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
JFJ. J. Feld
J. J. Feld
GKGregory J Kato
Gregory J Kato
CKC. Koh
C. Koh
TST. Shields
T. Shields
MHM. Hildesheim
M. Hildesheim
THT. Heller
T. Heller
Summary: Background: Increased life expectancy in sickle cell disease (SCD) has resulted in greater recognition of the consequences of repeated intravascular vaso‐occlusion and chronic haemolysis to multiple organ systems.Aim: To report the long‐term consequences of liver dysfunction in SCD.Methods: A cohort of SCD patients was prospectively evaluated at the National Institutes of Health (NIH) Clinical Center. The association of mortality with liver enzymes, parameters of liver synthetic function and iron overload was evaluated using Cox regression.Results: Exactly, 247 SCD patients were followed up for 30 months of whom 22 (9%) died. After controlling for predictors, increased direct bilirubin (DB), ferritin, alkaline phosphatase and decreased albumin were independently associated with mortality. In a multivariable model, only high DB and ferritin remained significant. Ferritin correlated with hepatic iron content and total blood transfusions but not haemolysis markers. Forty patients underwent liver biopsies and 11 (28%) had fibrosis. Twelve of 26 patients (48%) had portal hypertension by hepatic venous pressure gradient (HVPG) measurements. All patients with advanced liver fibrosis had iron overload; however, most patients (69%) with iron overload were without significant hepatic fibrosis. Ferritin did not correlate with left ventricular dysfunction by echocardiography. DB correlated with bile acid levels suggesting liver pathology. Platelet count and soluble CD14 correlated with HVPG indicating portal hypertension.Conclusions: Ferritin and direct bilirubin are independently associated with mortality in sickle cell disease. Ferritin likely relates to transfusional iron overload, while direct bilirubin suggests impairment of hepatic function, possibly impairing patients’ ability to tolerate systemic insults.

14 October 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
KHKoji Hara
Koji Hara
MRMaria M. Rivera
Maria M. Rivera
CKChristopher Koh
Christopher Koh
MDMary DeMino
Mary DeMino
SPSandra Page
Sandra Page
THTheo Heller
Theo Heller
Background. A sustained virological response (SVR) is the major end point of therapy for chronic hepatitis C virus (HCV) infection. Late relapse of infection is rare and poorly characterized. Three of 103 patients with a SVR treated at the National Institutes of Health had late relapse. We evaluated HCV RNA sequences in serum and liver tissue to distinguish relapse from reinfection. Methods. Per patient, 10–22 clones of amplified 5′ untranslated region were evaluated in pretreatment and relapse serum specimens and in liver biopsy specimens obtained during SVR. Genotypes and sequence diversity were evaluated. Four patients whose infection relapsed before they reached a SVR (ie, the early relapse group) were used as a comparison. Results. Results of tests for detection of serum HCV RNA in all patients with late relapse were repeatedly negative during the first 24 weeks after therapy but became positive 8, 75, and 78 months after SVR. Reinfection risk factors were absent in 2 of 3 patients. In all patients with early or late relapse, apart from minor variations, the original HCV sequence was present before treatment and after relapse. All liver biopsy specimens from patients with late relapse were HCV RNA positive at SVR, with sequences nearly identical to those of specimens obtained at other time points. Conclusions. Sequence comparisons suggest that reappearance of HCV RNA years after a SVR can be from relapse of the initial viral infection rather than reinfection from a different virus.